Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Vir Biotechnology
Biotech
Vir's hep B program fails to hit efficacy mark in phase 2
Vir's sidelined hepatitis B candidate, designed to serve as a “functional cure,” has failed to achieve the efficacy results.
Gabrielle Masson
May 9, 2025 9:35am
Vir won't advance potential hep B 'cure' without a partner
Feb 27, 2025 11:37am
Vir gains 3 T-cell engagers from Sanofi, lays off 25% of staff
Aug 2, 2024 6:12am
Vir keeps pressure on Gilead with midphase hepatitis D data
Jun 5, 2024 8:52am
Roche, Vir, Neurocrine & more—Chutes & Ladders
May 31, 2024 8:30am
How Vir found the one: CEO Marianne De Backer
Apr 19, 2024 10:27am
